YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimil...
Mindray , a leading global developer of healthcare technologies, launched its BeneVision V Series patient monitoring solution at Euroanaesthes...
Endurance Bio Inc., a clinical-stage biotechnology company developing therapies for neurodegenerative and metabolic diseases, today announced that its co...
The strategic collaboration with Broad Clinical Labs will explore and develop applications using Roche’s SBX sequencing technology1, with an init...
Invivyd, Inc. announced that PEMGARDA® (pemivibart), its investigational monoclonal antibody, has been added to the National Comprehensive Cancer Net...
SpringWorks Therapeutics, Inc. , a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the Europe...
Positive recommendation based on phase III INAVO120 data showing ItovebiTM (inavolisib) in combination with palbociclib and fulvestrant more than doubl...
Partnership designed to expand QIAGEN’s leadership in oncology-focused digital PCR assays, advancing QIAcuity as the platform of choice for can...
Eli Lilly and Company announced that the Australian Therapeutic Goods Administration (TGA) has granted marketing authorization for Kisunla (d...
MedX Health Corp. , a global leader in teledermatology, is pleased to announce a strategic collaboration in the Italian healthcare market between Vitamed...
Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, announced the compa...
Collaboration brings together complementary capabilities to co-develop and co-commercialize SRSD107, a next generation, long-acting Factor XI (FXI) small...
Enabled by WuXi Biologics' industry-leading integrated technology platform, velaglucerase-beta for injection has successfully advanced from concept to ...
Shanghai Ark Biopharmaceutical announced positive top-line Phase II study results for its novel anti-fibrotic drug AK3280 in treatment of idiopathic...
© 2025 Biopharma Boardroom. All Rights Reserved.
